A phase 2a trial of the IL-33 mAb tozorakimab in patients with COPD: FRONTIER-4

A phase 2a trial of the IL-33 mAb tozorakimab in patients with COPD: FRONTIER-4

Interleukin-33 may have a role in COPD pathobiology. FRONTIER-4 (NCT04631016) investigated tozorakimab (an anti-IL-33 monoclonal antibody) in moderate-to-severe COPD patients with chronic bronchitis receiving dual or triple inhaled therapy. FRONTIER-4 was a phase 2a, randomized, double-blind, placeb...

Whakaahuatanga katoa

I tiakina i:
Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua: Dave Singh, Patricia Guller, Fred Reid, Sarah Doffman, Ulla Seppälä, Ioannis Psallidas, Rachel Moate, Rebecca Smith, Joanna Kiraga, Eulalia Jiménez, Dennis E. Brooks, Aoife Kelly, Lars H. Nordenmark, Muhammad Waqas Sadiq, Luis Mateos Caballero, Chris Kell, Maria G. Belvisi, Hitesh Pandya
Hōputu: Artigo
Reo:Ingarihi
I whakaputaina: 2025
Urunga tuihono:https://doi.org/10.1183/13993003.02231-2024
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
Me noho koe te mea tuatahi ki te waiho tākupu!
Me takiuru i te tuatahi

Ngā tūemi rite